NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 57.3% in March

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 116,100 shares, a decline of 57.3% from the February 29th total of 271,700 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average daily volume of 3,350,000 shares, the short-interest ratio is currently 0.0 days.

NovaBay Pharmaceuticals Stock Performance

NYSEAMERICAN NBY traded down $0.01 during mid-day trading on Thursday, hitting $0.10. The stock had a trading volume of 1,981,271 shares, compared to its average volume of 3,657,216. NovaBay Pharmaceuticals has a twelve month low of $0.10 and a twelve month high of $1.95. The company has a market cap of $440,778.58, a P/E ratio of -0.01 and a beta of 2.82.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC increased its holdings in shares of NovaBay Pharmaceuticals by 57.5% during the 1st quarter. Renaissance Technologies LLC now owns 201,222 shares of the biopharmaceutical company’s stock worth $60,000 after buying an additional 73,500 shares during the last quarter. Virtu Financial LLC increased its stake in NovaBay Pharmaceuticals by 260.4% during the first quarter. Virtu Financial LLC now owns 163,451 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 118,099 shares during the last quarter. Finally, Armistice Capital LLC purchased a new stake in NovaBay Pharmaceuticals in the fourth quarter valued at $289,000. Hedge funds and other institutional investors own 1.34% of the company’s stock.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.